{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:17:41Z","timestamp":1755217061775,"version":"3.43.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>We report a case of recurrent undifferentiated pleomorphic sarcoma (UPS) in the right calf of a 48-year-old female patient who had undergone initial surgical resection in February 2018. The patient underwent two sessions of transcatheter arterial chemoembolization (TACE) between June and July 2022. During the procedures, superselective catheterization of the tumor-feeding arteries via the posterior tibial artery was performed, followed by infusion of epirubicin and sequential embolization with lipiodol, 300-500 \u03bcm microspheres, and gelatin sponges. Post-procedural angiography confirmed complete vascular occlusion. Clinical and imaging follow-up demonstrated significant tumor necrosis (60-70%) at one month post-treatment with progressive tumor shrinkage and central liquefaction. The disease remained stable at six months without distant metastasis. While literature reports of TACE for advanced sarcomas show PFS of 6.3\u201321 months, our case achieved 36-month PFS in locally recurrent non-metastatic UPS\u2014suggesting greater efficacy in earlier disease stages. During 36 months of follow-up, sustained local control was achieved without systemic progression. These findings suggest that for vascular-rich recurrent UPS when surgical resection is challenging, TACE represents a feasible locoregional therapeutic option.<\/jats:p>","DOI":"10.3389\/fonc.2025.1631000","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T05:24:35Z","timestamp":1754371475000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Three-year follow-up of TACE for recurrent undifferentiated pleomorphic sarcoma: sustained local control and no systemic progression"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiangrui","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengluo","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02712-6","article-title":"Current and emerging systemic treatment options for Malignant fibrous histiocytoma\/undifferentiated pleomorphic sarcoma","author":"Miwa","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2021.08.011","article-title":"Overview of Malignant soft-tissue sarcomas of the limbs","volume":"76","author":"Renn","year":"2021","journal-title":"Clin radiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.21037\/cco-23-71","article-title":"A systematic review of undifferentiated pleomorphic sarcoma of the chest wall","volume":"12","author":"Bennett","year":"2023","journal-title":"Chin Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3747\/co.27.5407","article-title":"Immunotherapy in soft-tissue sarcoma","volume":"27","author":"Ayodele","year":"2020","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01054-7","article-title":"A league of its own? Established and emerging therapies in undifferentiated pleomorphic sarcoma","volume":"24","author":"Graves","year":"2023","journal-title":"Curr Treat options Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"122540","DOI":"10.1016\/j.lfs.2024.122540","article-title":"Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure","volume":"342","author":"Li","year":"2024","journal-title":"Life Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/life13071485","article-title":"Transarterial embolization and percutaneous ablation of primary and metastatic soft tissue tumors","volume":"13","author":"Shu","year":"2023","journal-title":"Life (Basel Switzerland)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2022.03.006","article-title":"Management of myxofibrosarcoma and undifferentiated pleomorphic sarcoma","volume":"31","author":"Crago","year":"2022","journal-title":"Surg Oncol Clinics North A"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1109491","article-title":"Current research and management of undifferentiated pleomorphic sarcoma\/myofibrosarcoma","volume":"14","author":"Sun","year":"2023","journal-title":"Front Genet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1069963","article-title":"Exploring the landscape of immunotherapy approaches in sarcomas","volume":"12","author":"Pilavaki","year":"2022","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082287","article-title":"Current landscape of immunotherapy for advanced sarcoma","volume":"15","author":"Albarr\u00e1n","year":"2023","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010010","article-title":"Novel therapeutics in soft tissue sarcoma","volume":"17","author":"Mavroeidis","year":"2024","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-00944-6","article-title":"Immunotherapy and biomarkers in sarcoma","volume":"23","author":"Dajsakdipon","year":"2022","journal-title":"Curr Treat options Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4368-24","article-title":"A rare case of primary hepatic undifferentiated pleomorphic sarcoma: exploring cancer-related gene mutations","volume":"64","author":"Suzuki","year":"2025","journal-title":"Internal Med (Tokyo Japan)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2018.03.049","article-title":"TransArterial ChemoEmbolization (TACE) with platinum versus anthracyclines for hepatocellular carcinoma: A meta-analysis","volume":"53","author":"Zhao","year":"2018","journal-title":"Int J Surg (London England)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.007","article-title":"The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy","volume":"67","author":"Galle","year":"2017","journal-title":"J hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data","volume":"64","author":"Lencioni","year":"2016","journal-title":"Hepatol (Baltimore Md)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12957-017-1286-1","article-title":"Sarcomatoid hepatocellular carcinoma (SHC): a case report","volume":"15","author":"Yu","year":"2017","journal-title":"World J Surg Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12893-019-0562-0","article-title":"Transcatheter arterial chemoembolization improves the resectability of Malignant breast phyllodes tumor with angiosarcoma component: a case report","volume":"19","author":"Kuo","year":"2019","journal-title":"BMC surg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S502611","article-title":"A case of DEB-TACE combined with anlotinib for treatment of liver metastasis from retroperitoneal leiomyosarcoma","volume":"12","author":"Cui","year":"2025","journal-title":"J hepatocellular carcinoma"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2530-3","article-title":"Drug-eluting bead transarterial chemoembolization in the treatment for unresectable soft tissue sarcoma refractory to systemic chemotherapy: a preliminary evaluation of efficacy and safety","volume":"144","author":"Ni","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2014.11.034","article-title":"Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver - the use of imaging biomarkers as predictors of patient survival","volume":"84","author":"Chapiro","year":"2015","journal-title":"Eur J radiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.3332\/ecancer.2025.1933","article-title":"Primary treated versus referred trunk and extremities soft tissue sarcomas: comparative analysis of initial treatment impact on disease control","volume":"19","author":"Nardi","year":"2025","journal-title":"Ecancermedicalscience"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030401","article-title":"Principles of surgical treatment of soft tissue sarcomas","volume":"17","author":"Gonzalez","year":"2025","journal-title":"Cancers"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/his.14446","article-title":"Unravelling undifferentiated soft tissue sarcomas: insights from genomics","volume":"80","author":"Hames-Fathi","year":"2022","journal-title":"Histopathology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1631000\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T05:24:36Z","timestamp":1754371476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1631000\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":25,"alternative-id":["10.3389\/fonc.2025.1631000"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1631000","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"article-number":"1631000"}}